|84.93||+2.27||+2.75%||Vol 956.68K||1Y Perf 21.23%|
|Apr 16th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||93.75||Analyst Rating||Strong Buy 1.54|
|Potential %||10.39||Finscreener Ranking||★★★ 49.57|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★ 47.03|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★ 59.99|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||★+ 39.07|
|Market Cap||8.43B||Earnings Rating||Sell|
|Price Range Ratio 52W %||88.14||Earnings Date||27th Apr 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||27th Apr 2021|
|Estimated EPS Next Report||0.80|
|EPS Growth Next 5 Years %||15.60|
|Avg. Weekly Volume||428.75K|
|Avg. Monthly Volume||606.79K|
|Avg. Quarterly Volume||659.46K|
Encompass Health Corporation (NYSE: EHC) stock closed at 84.93 per share at the end of the most recent trading day (a 2.75% change compared to the prior day closing price) with a volume of 956.74K shares and market capitalization of 8.43B. Is a component of Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 43178 people. Encompass Health Corporation CEO is Mark J. Tarr.
The one-year performance of Encompass Health Corporation stock is 21.23%, while year-to-date (YTD) performance is 2.71%. EHC stock has a five-year performance of 145.37%. Its 52-week range is between 58.99 and 88.42, which gives EHC stock a 52-week price range ratio of 88.14%
Encompass Health Corporation currently has a PE ratio of 28.70, a price-to-book (PB) ratio of 5.12, a price-to-sale (PS) ratio of 2.33, a price to cashflow ratio of 11.60, a PEG ratio of 2.32, a ROA of 4.33%, a ROC of 7.84% and a ROE of 18.51%. The company’s profit margin is 7.45%, its EBITDA margin is 19.40%, and its revenue ttm is $3.46 Billion , which makes it $34.88 revenue per share.
Of the last four earnings reports from Encompass Health Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.80 for the next earnings report. Encompass Health Corporation’s next earnings report date is 27th Apr 2021.
The consensus rating of Wall Street analysts for Encompass Health Corporation is Strong Buy (1.54), with a target price of $93.75, which is +10.39% compared to the current price. The earnings rating for Encompass Health Corporation stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Encompass Health Corporation has a dividend yield of 1.38% with a dividend per share of $1.12 and a payout ratio of 41.00%.
Encompass Health Corporation has a Buy technical analysis rating based on Technical Indicators (ADX : 6.60, ATR14 : 2.21, CCI20 : 230.41, Chaikin Money Flow : 0.04, MACD : 0.17, Money Flow Index : 40.82, ROC : 2.57, RSI : 63.04, STOCH (14,3) : 88.81, STOCH RSI : 1.00, UO : 52.86, Williams %R : -11.19), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Encompass Health Corporation in the last 12-months were: Andrew Price (Sold 8 589 shares of value $699 145 ), Barbara Jacobsmeyer (Sold 2 500 shares of value $161 825 ), Douglas E. Coltharp (Option Excercise at a value of $568 959), Douglas E. Coltharp (Sold 23 501 shares of value $1 779 937 ), Elissa Joy Charbonneau (Sold 6 650 shares of value $500 213 ), Mark J. Tarr (Option Excercise at a value of $549 295), Mark J. Tarr (Sold 26 132 shares of value $1 618 093 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.